90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years

Kathrin Rieger1 · Rosaria De Filippi2,3 · Ola Lindén4 · Andreas Viardot5 · Georg Hess6 · Kristina Lerch1 · Peter Neumeister7 · Andrea Stroux8 · Caroline A. Peuker1 · Antonio Pezzuto1 · Antonello Pinto3 · Ulrich Keller1,9,10,11 · Christian W. Scholz1,12

Received: 2 November 2021 / Accepted: 27 January 2022 / Published online: 12 February 2022 © The Author(s) 2022

Abstract

Radioimmunotherapy with 90-yttrium-ibritumomab tiuxetan (90Y-IT) as first-line treatment in patients with follicular lymphoma (FL) demonstrated promising results with a complete remission (CR) rate of 56% and a median progression-free survival (PFS) of 26 months, when initially analyzed after a median follow-up of 30.6 months. The aim of this long-term follow-up was to investigate whether clinical benefits were maintained and new safety signals appeared. Fifty-nine patients, aged ≥ 50 years, with FL grade 1 to 3A in stages II to IV were treated with 90Y-IT as first-line therapy. If CR without evidence of minimal residual disease (MRD), partial response or stable disease was achieved 6 months after treatment, patients were observed without further treatment. Patients with CR but persisting MRD received consolidation therapy with rituximab. The primary endpoint was the clinical response rate. Secondary endpoints were time to progression, safety, and tolerability. After a median follow-up of 9.6 years, median PFS was 3.6 years, and 8-year PFS was 38.3%. Median overall survival (OS) was not reached during the extended follow-up, and 8-year OS amounted to 69.2%. Age 65 years and above or disease progression within 24 months of treatment were significantly associated with shorter OS. An important finding was the lack of new safety signals. In particular, no increase in secondary malignancies or transformation into aggressive lymphoma was observed compared to trials with a similar follow-up. In summary, 90Y-IT as first-line treatment demonstrates a favorable safety profile and long-term clinical activity in a substantial fraction of FL patients in need of therapy. ClinicalTrials.gov Identifier: NCT00772655.

Keywords Follicular lymphoma · First-line therapy · 90-yttrium-ibritumomab tiuxetan · 90Y-IT

1 Department of Hematology, Oncology and Cancer Immunology, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité – Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany
2 Department of Clinical Medicine and Surgery, Università degli Studi di Napoli Federico II, Naples, Italy
3 National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy
4 Lund University Hospital, Lund, Sweden
5 Department of Internal Medicine III, University Ulm, Ulm, Germany
6 Johannes-Gutenberg-University, Mainz, Germany
7 Medical University Graz, Graz, Austria
8 Institute for Biometry and Clinical Epidemiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
9 Internal Medicine III, Technische Universität München, Munich, Germany
10 German Cancer Consortium (DKTK), partner site Charité – Universitätsmedizin Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany
11 Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
12 Vivantes Klinikum Am Urban, Berlin, Germany
**Introduction**

Follicular lymphoma (FL) is an indolent non-Hodgkin lymphoma, frequently diagnosed at an advanced stage, i.e., Ann Arbor stage III or IV. Only about 15 to 25% of the cases are diagnosed at stage I or II [1]. Patients with stage III and IV and low tumor burden according to GELF (Groupe d'Etudes des Lymphomes Folliculaires) criteria are generally only observed (watchful waiting) [2, 3], while individuals with advanced disease and high tumor burden and/or symptomatic lymphoma receive chemoimmunotherapy, i.e., bendamustine or CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or CVP (cyclophosphamide, vincristine, prednisone) [4, 5] in combination with the anti-CD20 antibodies rituximab (R) or obinutuzumab (O) [6]. R or O maintenance therapy has been approved and is frequently applied [7–9]. Although FL is a highly radiosensitive disease, external beam radiotherapy (EBRT) is not used upfront in advanced disease and is only infrequently applied in later treatment lines, mainly for palliative purposes. In stage I, or limited stage II FL, EBRT is applied as a curative treatment approach at the time of diagnosis [3]. Recent data from two phase II trials indicate that the addition of R to EBRT increases progression-free survival (PFS) [10, 11]. Radioimmunotherapy (RIT) combines treatment modalities of immuno- and radiotherapy. The radionuclide 90-Yttrium linked to the anti-CD20 antibody ibritumomab through the linker tiuxetan (90Y-IT, Zevalin®) has demonstrated efficacy as consolidation therapy after first-line chemotherapy [12–15] and in relapsed FL [15]. Side effects of 90Y-IT include in particular neutro-, lympho-, and thrombocytopenia between weeks 6 and 9 after application and are generally well manageable. Severe infections and the need for transfusions are rare if RIT is used in early treatment lines in the absence of severe bone marrow infiltration. Based on these notions, we conducted the first phase II study with 90Y-IT as a stand-alone upfront treatment for patients with advanced stage FL who required treatment. In our first analysis after a median follow-up of 30 months, the overall response rate was 82% (complete response (CR)/CR unconfirmed (CRu) 56%) and median PFS was 26 months [16]. Here, we present updated efficacy and safety results after an extended median follow-up of 9.6 years.

**Methods**

**Patients**

Patient characteristics have been described in detail before [16] and are summarized in Table 1. Briefly, patients with untreated, histologically confirmed FL grade 1 to 3A in stages III to IV were included. Individuals with stage II FL were included if lesions would have required an extensive radiation field, i.e., an abdominal bath or similar radiation fields that were considered to be unfeasible by the investigator. However, this was not further specified in the protocol. Disease manifestations had to be measurable bidimensionally and patients had to have treatment indication

| Baseline characteristics | No. of patients (n = 59) | % |
|--------------------------|--------------------------|---|
| Age at assignment, years | Median 66.0 | Range 51–83 |
| Gender | Females 35 | 59% |
| | Males 24 | 41% |
| ECOG performance score | 0 45 | 76% |
| | 1 14 | 24% |
| Time from initial diagnosis, months | Median 2.0 | Range 0–70 |
| Ann Arbor classification, stage | I 0 | II 12 20% |
| | III 26 44% | IV 21 36% |
| | Bulky disease at least 5 cm 18 31% |
| Bone marrow infiltration | 0% 37 63% | 1–10% 6 10% |
| | 11–25% 16 27% |
| Grade REAL/WHO | 1 22 37% | 2 22 37% |
| | 2/3a 3 5% | 3a 11 19% |
| | Not classified 1 2% |
| LDH > upper limit of normal | 15 25% |
| FLIPI score | Low (≤ 1) 18 31% | Intermediate (2) 25 42% |
| | High (> 2) 16 27% |

Percentages are based on patients treated (n = 59) unless otherwise indicated.

*ECOG*, Eastern Cooperative Oncology Group; *FLIPI*, Follicular Lymphoma International Prognostic Index; *LDH*, lactate dehydrogenase; *REAL*, Revised European-American Lymphoma [classification]; *WHO*, World Health Organization [classification of lymphoid neoplasias 2016]
as defined by one of the following criteria: presence of B symptoms, lymphoma progression >50% within 6 months, organ compression caused by lymphoma lesions, bulky disease (>5 cm in at least one axis), or FL grade 3A. Due to safety concerns expressed by the local radiation safety authority, recruitment into the trial was limited to patients ≥50 years. Patients were ineligible for the trial, if one of the following situations was present: bone marrow infiltration by FL >25%, peripheral blood (pB) leukopenia (white blood cell count <2500/μl), thrombocytopenia (platelets <100,000/μl), circulating lymphoma cells in pB >500/μl, pleural effusion, ascites >1000 ml, bulky disease >10 cm in one axis, or central nervous system (CNS) involvement.

Study design and treatment

For this prospective, international, multicenter, non-randomized phase II study (NCT00772655) institutional review board approval from each center and informed consent from each patient were obtained. Patients received R 250 mg/m² on day 1 followed by 185 MBq 111indium for dosimetry. Subsequently, a second infusion of R 250 mg/m² followed by 15 MBq/kg 90Y-IT up to a maximum dose of 1200 MBq was administered on day 8 or 9. Response to treatment according to standard criteria [17] was assessed by computed tomography (CT) of the neck, thorax, abdomen, and pelvis every 6 months for 2 years and then once a year for additional 3 years. Patients who achieved a CR but showed evidence of molecular minimal residual disease (MRD) in pB or bone marrow received consolidation therapy with R 375 mg/m² once per week for 4 weeks, followed by 4 cycles of R 375 mg/m² every 8 weeks. Safety and tolerability of treatment were assessed according to Common Terminology Criteria for Adverse Events version 2.0 (CTCAE v2.0). After 5 years of follow-up, patients formally completed the study and were managed according to local guidelines.

Statistical analysis

The median and interquartile range were calculated for quantitative variables, as well as absolute and relative frequencies for categorical variables. PFS and OS were analyzed using the log-rank test. Results are shown as Kaplan–Meier plots. Cumulative incidences of secondary malignancies and transformation into aggressive lymphoma were estimated according to the Kaplan–Meier method. Cox regression analysis with forward and backward selection was performed to assess the effects of distinct baseline parameters that were significant in univariate analyses, e.g., age, gender, and LDH on PFS and OS. The influence of disease progression within 24 months (POD24) of treatment with 90Y-IT on OS was analyzed with a Cox proportional hazards model as a time-dependent covariate. In our study, POD24 is defined as relapse or disease progression within 24 months after initiation of treatment (modified definition) [18, 19], not after initial diagnosis (original definition). All statistical analyses were performed with the software PASW (IBM SPSS, Chicago, IL). Two-sided P-values ≤0.05 were considered significant. No Bonferroni adjustment was performed due to the exploratory character of this study.

Results

Patient characteristics

Between June 2007 and June 2010, 59 patients with histologically confirmed FL in need of treatment were included in the trial. All 59 patients were treated with 90Y-IT. Only 1 patient received R consolidation therapy subsequently to 90Y-IT according to study protocol. The median age at baseline was 66 years (range 51–83). 17 patients were aged >70 years and 9 patients >75 years at the time of treatment. Twelve patients had stage II disease and would have required extended field radiation, while 47 patients were either in stage III (n = 26) or stage IV (n = 21). Fourteen patients had grade 2-3A (n = 3) or grade 3A (n = 11) FL, while 45 individuals had FL grade 1–2 (Table 1). All patients fulfilled the treatment criteria as described above. If the GELF criteria had been applied to define high tumor burden, only 2 patients would not have qualified for treatment within the trial due to low tumor burden.

Clinical response and survival

Of the 59 treated patients, 47 were evaluable for response analysis at 24 months after treatment with 90Y-IT. Of these, 19 (40.4%) patients were in CR at the time, 3 in partial remission (6.4%), and 1 (2.1%) patient had stable disease, whereas disease progression within 24 months after treatment (POD24) was observed in 24 patients (51.1%). Intriguingly, of the 19 patients in CR 24 months after 90Y-IT, 12 patients (63.2%) remained in remission after a median follow-up of 9.6 years, i.e., 20% of all patients treated with 90Y-IT in this trial.

Median PFS for the entire patient cohort was 3.6 years (95% CI 0.42–6.68) (Fig. 1A). Eight-year PFS was 38.3%. As in our initial publication [16], in the extended follow-up cohort patients with elevated LDH levels at baseline had a significantly shorter PFS (P = 0.046) compared to those with normal levels. In contrast, gender did not have a significant impact on PFS (P = 0.552). Furthermore, there was no significant difference regarding PFS between patients ≥65 years at baseline as compared to individuals aged 50 to 64 years (P = 0.607) (Fig. 1B). A similar result was observed when
60 years ($P = 0.676$) were chosen as a cutoff or when age was applied as a constant variable in a Cox regression model ($P = 0.606$).

Median OS of the cohort has not been reached yet at the time of analysis and 8-year OS was 69.2\% (Fig. 2A). Patients with elevated LDH levels at baseline did not have a significantly shorter OS as compared to patients with normal LDH levels ($P = 0.498$). A similar result was observed when LDH was analyzed as a continuous variable in a Cox regression model ($P = 0.270$). Furthermore, gender had no impact on OS ($P = 0.552$). Likewise, being in CR 24 months after treatment with 90Y-IT as compared to not being in CR did not have a significant impact on OS ($P = 0.114$). The same applied for CR at 6, 12, and 18 months, i.e., $P = 0.893$, $P = 0.246$, and $P = 0.087$, respectively. However, patients who were 65 years or older at the time of 90Y-IT application had a significantly higher risk to die during follow-up compared to patients aged 50–64 years ($P = 0.002$) (Fig. 2B). Age applied as a continuous variable in a Cox regression analysis demonstrated a significant impact on OS as well ($P < 0.001$; HR 1.16). Finally, we observed a significantly shorter median OS in patients who experienced disease progression within 24 months of 90Y-IT treatment (POD24) as compared to patients without disease progression within 24 months ($P = 0.004$) in 47 evaluable patients.

**Fig. 1** Progression-free survival. a Progression-free survival after a median follow-up of 9.6 years among 59 patients treated. b Progression-free survival of patients aged 50–64 years (blue curve) as compared to patients ≥65 years (red curve) ($P = 0.607$).

**Fig. 2** Overall survival. a Overall survival after a median follow-up of 9.6 years among 59 patients treated. b Overall survival of patients aged 50–64 years (blue curve) as compared to patients ≥65 years (red curve) ($P = 0.002$). c Overall survival of patients with disease progression within 24 months of 90Y-IT treatment (POD24) (red curve) as compared to patients without disease progression within 24 months (blue curve) ($P = 0.004$) in 47 evaluable patients.
Toxicity and safety

Toxicity, which occurred during the first 2 years after treatment, has been reported before [16]. Briefly, CTCAE v2.0 grade 3 or 4 toxicities were exclusively hematologic, i.e., thrombocytopenia (48%), leukopenia (34%), neutropenia (32%), and lymphopenia (20%). Non-hematologic toxicities grade 3 or 4 were not observed.

With an extended follow-up of 9.6 years transformation into aggressive lymphoma was detected in 7 out of 51 evaluable patients (14%), with a cumulative incidence at 10 years of 13.2% (95% CI 12.2–27.6) (Fig. 3A). Secondary malignancies were observed in 9 out of 55 evaluable patients (16%) including breast cancer, adenocarcinoma of the lung, squamous cell carcinoma of the tongue, cutaneous squamous cell carcinoma, squamous cell carcinoma of head and neck, adenocarcinoma not further specified, CNS neoplasia (no histology obtained), and adenocarcinoma of the esophagus. One patient developed renal cancer as well as pancreatic cancer. Information regarding transformation and secondary malignancies during the prolonged follow-up could not be collected in 8 and 4 patients, respectively. One patient showed no evidence of transformation or secondary malignancy at a shorter follow-up of 5.5 years after treatment. Retrospectively, in two cases of secondary malignancies, signs of the malignant disease were already present before treatment with 90Y-IT. In 3 of the 8 patients, secondary malignancies were fatal. The cumulative incidence of all secondary malignancies at 10 years was 17.3% (95% CI 14.5–25.1) (Fig. 3B).

Discussion

After a median follow-up of 9.6 years, 90Y-IT application as first-line therapy for FL conferred a median PFS of 3.6 years and an 8-year PFS of 38%. Furthermore, 20% of the 59 patients remain in CR without further lymphoma treatment at the time of this analysis. Our results with an ORR of 87% and a CR/CRu rate of 31% were outperformed to some extent by another trial with 90Y-IT as first-line treatment in FL, demonstrating an ORR of 94%, a CR rate of 86% and an estimated 3-year PFS of 63% [20]. However, only 44% of the patients in that trial had a high tumor burden as defined by GELF criteria, whereas in our trial 96% of the patients would have met GELF criteria, i.e., only 2 of 59 patients did not fulfill GELF criteria. PFS achieved in our trial was comparable to the 8-year event-free survival of 45% reported for treatment-naïve patients who received 8 cycles of single-agent R [21]. However, in this trial, patients simply required a single enlarged lymph node ≥ 2 cm for inclusion into the trial, and the proportion of patients with high tumor burden was not disclosed. When comparing our findings to results of chemoimmunotherapies currently used as first-line treatment, i.e., R-CVP, R-CHOP, or R-bendamustine, treatment with 8 cycles of R-CVP let to a median PFS of 32 months in FL patients who required treatment in the opinion of the treating clinician, which was not further specified [4]. In a clinical trial comparing 6 cycles of R-CHOP to R-bendamustine, median PFS was 40.9 months as compared to a median PFS which has not been reached yet after a follow-up of 45 months (3-year PFS 70%) [22]. In another trial comparing R-CHOP/R-CVP to R-bendamustine, PFS amounted to 40 months as compared to a median PFS which has not been reached yet after a follow-up of 5 years (5-year PFS 58%), respectively [5]. Therefore, PFS achieved with 90Y-IT, i.e., with a single infusion, appears to be comparable to PFS obtained with R-CVP or even R-CHOP.

Apart from analyzing long-term toxicity, the benefit of an extended follow-up is the assessment of OS. Regarding our trial, median OS has not been reached yet after a median follow-up of 9.6 years and 8-year OS was 69%. Notably,
POD24 was significantly associated with a shortened OS. While this has been previously demonstrated in FL patients given chemoimmunotherapy [18], more recent studies have highlighted that the predictive impact of POD24 may be prognostic, independent of the type of treatment, and is also applicable to chemotherapy-free regimens [23].

OS demonstrated in our trial is similar to the OS of 68% reported in the trial with R monotherapy after a median follow-up of 9.3 years [21]. However, the median age at trial inclusion was 66 years (range, 51–83) in our trial, while patients in the R monotherapy trial had a median age of 57 years (range, 28–81). The reason for this difference was the prerequisite that patients had to be 50 years or older to participate in our trial, due to the request of the German radiation safety authority. Unfortunately, there is no long-term follow-up data available for the before-mentioned trials examining R-CVP, R-CHOP, and R-bendamustine. However, 8-year OS reported for FL patients treated with a R-CHOP-like regimen, i.e., R-CHVP (cyclophosphamide, doxorubicine, etoposide, prednisolone) plus interferon-α2a amounted to 78% [24]. Notably, the median age in this trial was 61 years (range, 25–75). Regarding results from the PRIMA trial, where FL patients received chemoimmunotherapy (R-CVP, R-CHOP, R-FCM (fludarabine, cyclophosphamide, mitoxantrone)) followed by 12 cycles of R maintenance therapy every 2 months, 10-year OS resulted in 80%, which is superior to OS data from our trial. However, the median age at trial inclusion was only 56 years (range, 22–87) in the PRIMA trial [8]. We demonstrate in our trial that age at study entry had a significant impact on the likelihood of death, and patients > 65 years had a significantly higher risk to die. Therefore, age distribution may be an important factor when putting results from one specific trial in FL patients into a larger clinical context.

Regarding long-term toxicity, we observed 9 secondary malignancies (16%) in 55 evaluable patients during a median follow-up of 9.6 years. If the 2 patients are excluded who retrospectively already showed signs of the malignancy before treatment, the incidence of secondary malignancies would drop to 13% in our trial. This is similar to the R monotherapy trial where 23 secondary malignancies in 151 patients (15%) were reported during a follow-up of 9.3 years [21] or 9% and 7% secondary malignancies following R-CHOP and R-bendamustine therapy, respectively, after a median follow-up of only 45 months [22]. Concerning the lower rate of secondary malignancies in the R-bendamustine trial, the shorter follow-up time and the lower median age of the patients have to be taken into account [22]. The 10-year cumulative incidence of secondary malignancies in our cohort was comparable to recently published data comparing single-dose consolidation therapy with 90Y-IT as stand-alone frontline therapy and may prompt including this endpoint in further RIT trials.

In conclusion, after an extended follow-up of more than 9 years, 90Y-IT remains an effective and safe upfront treatment for patients with FL requiring therapy. While availability and application of 90Y-IT have been an issue over the last years, our data support the validity and safety of RIT-based upfront therapy and prompt further trials of novel antibody-radionuclide-conjugates as frontline treatment of FL [30, 31].

Acknowledgements The authors wish to thank all patients who participated in the clinical trial and all investigators and study personnel at the sites.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Ethics approval This study (NCT00772655) was performed in line with the principles of the Declaration of Helsinki. Institutional review board approval from each center and informed consent from each patient were obtained.
Conflict of interest K.R. has received honoraria from Roche, BMS, Amgen, Novartis, Janssen-Cilag, and Abbvie, and reports consultant/ advisory roles for MSD and Essex Pharma. A.V. has received honoraria from Roche, Amgen, Kite/Gilead, Novartis, and BMS, and reports consultant/advisory roles for Roche, Amgen, Kite/Gilead, Novartis, and BMS. C.A.P. has received honoraria from BMS, Novartis, Daiichi-Sankyo, EUSA Pharma, and Sirteix Medical, and reports a consultant/advisory role for EUSA Pharma. U.K. reports consultant/advisory roles for Roche, BMS, Celgene, Novartis, Gilead, Pentaxapharm, EUSA Pharma, Janssen-Cilag, AstraZeneca, Hexal, MSD, Takeda, and Amgen. C.W.S. has received honoraria from GILEAD, Janssen, Pfizer, and Roche, and reports consultant/advisory roles for BMS, Celgene, Daiichi-Sankyo, GILEAD, Hexal, Janssen, Merck Serono, Novartis, and Takeda. The other authors have no competing interests to declare that are relevant to the content of this article.

Data sharing statement Clinical data contains potentially personal information and is stored with the authors. Upon request, it can be shared in anonymized form with the editors or fellow scientists.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Mondello P, Steiner N, Wasle I, Pitini V, Mian M (2014) Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal? Anticancer Res 34(11):6701–6704
2. Bricc P, Bastion Y, Lepage E et al (1997) Comparison in low-tumour burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires, Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 15(3):1110–7
3. Dreyling M, Ghelimi M, Rule S et al (2016) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v83–v90
4. Marcus R, Imrie K, Solal-Celigny P et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26(28):4579–4586
5. Flinn IW, van der Jagt R, Kahl B et al (2019) First-Line Treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol 37(12):984–991
6. Marcus R, Seymour JF, Hiddemann W (2017) Obinutuzumab treatment of follicular lymphoma. N Engl J Med 377(26):2605–2606
7. Salles G, Seymour JF, Ofner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42–51
8. Bach E, Seymour JF, Feugier P et al (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 37(31):2815–2824
9. Hiddemann W, Barbui AM, Canales MA et al (2018) Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol 36(23):2395–2404
10. Herfarth K, Borichmann P, Schnaidt S et al (2018) Rituximab with involved field irradiation for early-stage nodal follicular lymphoma: results of the MIR study. Hemasphere. 2(6):e160
11. Ruella M, Filippini AR, Bruna R et al (2016) Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study. Int J Radiat Oncol Biol Phys 94(4):783–791
12. Casadei B, Pellegrini C, Pulsoni A et al (2016) 90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years. Cancer Med 5(6):1093–1097
13. Morschhauser F, Radford J, Van Hoof A et al (2013) 90Yttrium-ibritumomab tiuxetan consolidation of first-line treatment in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J Clin Oncol. 31(16):1977–83
14. Provencio M, Cruz Mora MA, Gomez-Codina J et al (2014) Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. Leuk Lymphoma 55(1):51–55
15. Witzig TE, Gordon LI, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463
16. Scholz CW, Pinto A, Linkesch W et al (2013) (90)Yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 31(3):308–313
17. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NC1 Sponsered International Working Group. J Clin Oncol 17(4):1244
18. Casulo C, Byrtek M, Dawson KL et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphoma Care Study. J Clin Oncol 33(23):2516–2522
19. Jurinovic V, Kridel R, Staiger AM et al (2016) Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 128(8):1112–1120
20. Ibiatici A, Pica GM, Nati S et al (2014) Safety and efficacy of (90) yttrium-ibritumomab tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Br J Haematol 164(5):710–6
21. Martinelli G, Schmitz SF, Utiger U et al (2010) Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 28(29):4480–4484
22. Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210

23. Moccia AA, Schar S, Hayoz S et al (2020) Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol 192(6):1031–1034

24. Bachy E, Houot R, Morschhauser F et al (2013) Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica 98(7):1107–1114

25. Lopez-Guillermo A, Canales MA, Dlouhy I et al (2021) A randomized phase II study comparing consolidation with a single dose of (90)Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. Leuk Lymphoma 63(1):93–100

26. Rizzieri D (2016) Zevalin® (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? Crit Rev Oncol Hematol 105:5–17

27. Al-Tourah AJ, Gill KK, Chhanabhai M et al (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol 26(32):5165–5169

28. Link BK, Maurer MJ, Nowakowski GS et al (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31(26):3272–3278

29. Sarkozy C, Trneny M, Xerri L et al (2016) Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol 34(22):2575–2582

30. Dolgin E (2018) Radioactive drugs emerge from the shadows to storm the market. Nat Biotechnol 36(12):1125–1127

31. Sgouros G, Bodei L, McDevitt MR, Nedrow JR (2020) Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 19(9):589–608

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.